Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: A prospective study

Archives of Surgery

Volumn 147, Issue 3, 2012, Pages 251-255

  Talving, Peep ^a   Lustenberger, Thomas ^a   Inaba, Kenji ^a   Lam, Lydia ^a   Mohseni, Shahin ^a   Chan, Linda ^a   Demetriades, Demetrios ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; FEMALE; GLASGOW COMA SCALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; SEPSIS; STATISTICAL SIGNIFICANCE; SURVIVAL; TRAUMATIC BRAIN INJURY; VITAL SIGN;

ABBREVIATED INJURY SCALE; ADULT; BRAIN INJURIES; CASE-CONTROL STUDIES; ERYTHROPOIETIN; FEMALE; GLASGOW COMA SCALE; HEMATINICS; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPENSITY SCORE; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84858775415     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2011.1838     Document Type: Article

References (29)

1. Hukkelhoven CW, Steyerberg EW, Rampen AJ, et al. Patient age and outcome following severe traumatic brain injury: an analysis of 5600 patients. J Neurosurg. 2003;99(4):666-673. (Pubitemid 37159043)
2. Thurman DJ, Alverson C, Dunn KA, Guerrero J, Sniezek JE. Traumatic brain injury in the United States: a public health perspective. J Head Trauma Rehabil. 1999;14(6):602-615. (Pubitemid 30027268)
3. Myburgh JA, Cooper DJ, Finfer SR, et al; Australasian Traumatic Brain Injury Study (ATBIS) Investigators for the Australian; New Zealand Intensive Care Society Clinical Trials Group. Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New Zealand. J Trauma. 2008;64(4):854-862.
4. Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med. 1999;340(24): 1881-1887. (Pubitemid 29272669)
5. Grasso G, Buemi M, Alafaci C, et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A. 2002;99(8):5627-5631. (Pubitemid 34411600)
6. Grasso G, Graziano F, Sfacteria A, et al. Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage. Neurosurgery. 2009;65(4):763-769, discussion 769-770.
7. Grasso G, Sfacteria A, Meli F, Fodale V, Buemi M, Iacopino DG. Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res. 2007;1182:99-105. (Pubitemid 350086993)
8. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000; 97(19):10526-10531.
9. Talving P, Lustenberger T, Kobayashi L, et al. Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study. Ann Surg. 2010;251(1):1-4.
10. Nichol AD, Cooper DJ; POLAR Study Investigators on behalf of the ANZICS - Clinical Trials Group; EPO Study Investigators on behalf of the ANZICS - Clinical Trials Group. Can we improve neurological outcomes in severe traumatic brain injury? something old (early prophylactic hypothermia) and something new (erythropoietin). Injury. 2009;40(5):471-478.
11. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994;91(9):3974-3978. (Pubitemid 24139555)
12. Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci. 2004;22(2):105-119. (Pubitemid 38850338)
13. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293(1):90-95. (Pubitemid 40066704)
14. Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab. 2002;22(5):503-514. (Pubitemid 34477771)
15. Maiese K, Chong ZZ. Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease. Restor Neurol Neurosci. 2004;22(2):87-104. (Pubitemid 38850337)
16. Sakamaki K. Regulation of endothelial cell death and its role in angiogenesis and vascular regression. Curr Neurovasc Res. 2004;1(4):305-315.
17. Chong ZZ, Kang JQ, Maiese K. Angiogenesis and plasticity: role of erythropoietin in vascular systems. J Hematother Stem Cell Res. 2002;11(6):863-871. (Pubitemid 36139767)
18. Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab. 2003;23(3):320-330. (Pubitemid 36307576)
19. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002;106(23):2973-2979. (Pubitemid 35424751)
20. Doetsch F, Caillé I, Lim DA, García-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell. 1999; 97(6):703-716. (Pubitemid 29278045)
21. Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci. 2001;21(24):9733-9743. (Pubitemid 34184059)
22. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics. 2008;122(2):383-391.
23. Fauchère JC, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 2008;122 (2):375-382.
24. Ehrenreich H, Weissenborn K, Prange H, et al; EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40(12):e647-e656.
25. Corwin HL, Gettinger A, Pearl RG, et al; EPO Critical Care Trials Group. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002;288(22):2827-2835. (Pubitemid 35425068)
26. Corwin HL, Gettinger A, Fabian TC, et al; EPO Critical Care Trials Group. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357(10): 965-976. (Pubitemid 47367076)
27. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914-924. (Pubitemid 351397066)
28. Corwin HL. The role of erythropoietin therapy in the critically ill. Transfus Med Rev. 2006;20(1):27-33. (Pubitemid 41811225)
29. Napolitano LM, Fabian TC, Kelly KM, et al. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J Trauma. 2008;65 (2):285-297, discussion 297-299.